# US 2022/0031725 A1 · Treatment of aging-associated conditions by dna degradation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031725 A1
- Document ID: US20220031725A1
- Status: Published application
- Kind: A1
- Application number: 17/279,280
- Filed: 2019-09-25
- Published: 2022-02-03
- Earliest claimed: 2018-09-25
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Yuk Yuen Lan; Nir Hacohen
- Web page: https://patentgrep.com/patent/US20220031725A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12Y 301/22001: Deoxyribonuclease II (3.1.22.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Provided herein, in some embodiments, are methods for treating age-associated conditions, including systemic inflammation and disease, via enhanced DNA degradation.

## Claims

### Claim 1

A method for treating an aging-associated condition in a subject, comprising:
increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.

### Claim 2

A method for protecting against an aging-associated condition in a subject, comprising:
increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the increased expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject is facilitated by systemic or local administration of a DNase enzyme.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the increased expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject is facilitated by gene therapy.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein the increased expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject is facilitated by administration of a small molecule to the subject.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the DNase enzyme is a lysosomal nuclease enzyme.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the DNase enzyme is DNASE2A.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the DNase enzyme is a derivative of DNASE2A.

### Claim 9 (depends on 8)

The method of claim 8, wherein the derivative of DNASE2A is functionally enhanced relative to DNASE2A.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the aging-associated condition is aging-associated inflammation and cellular senescence.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the aging-associated condition is a laminopathy.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the aging-associated condition is an interferonopathy.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the aging-associated condition is ataxia telangiectasia (A-T).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the aging-associated condition is Hutchison-Gilford progeria.

### Claim 15 (depends on 10)

The method of claim 10, wherein the aging-associated inflammation and cellular senescence is induced or enhanced by treatment with a chemotherapeutic agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein said chemotherapeutic agent is a DNA damaging agent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the DNA damaging agent is cytarabine (ara-C).

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the subject is identified as having elevated levels of extranuclear DNA relative to a control.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the subject is identified as having elevated levels of SA-β-gal activity relative to a control.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the subject is identified as having elevated levels of:
(i) one or more autophagy genes, optionally ATG5, BECLIN1, P62, or PTEN;
(ii) one or more autophagosome marker, optionally LC3;
(iii) one or more lysosomal protein, optionally LAMP1; and/or
(iv) one or more inflammatory genes, optionally MX1, CXCL10, or IL-6 relative to a control.

### Claim 21

A method for treating an aging-associated condition in a subject, comprising:
identifying a subject as having elevated levels of extranuclear DNA relative to a control; and increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.

### Claim 22

A method for treating an aging-associated condition in a subject, comprising:
identifying a subject as having elevated levels of SA-β-gal activity relative to a control; and increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.

### Claim 23

A method for treating an aging-associated condition in a subject, comprising:
identifying a subject as having elevated levels of:
(i) one or more autophagy genes, optionally ATG5, BECLIN1, P62, or PTEN;
(ii) one or more autophagosome marker, optionally LC3;
(iii) one or more lysosomal protein, optionally LAMP1; and/or
(v) one or more inflammatory genes, optionally MX1, CXCL10, or IL-6 relative to a control; and
increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The method of any one of claims 18-23, wherein the control is a sample from a subject who does not have an aging-associated condition.

### Claim 25 (depends on 18, 19, 20, 21, 22, 23)

The method of any one of claims 18-23, wherein the control is a predetermined value.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the subject is a human.
